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Abstract
Background: Colorectal cancer can be efficiently treated when found at early stages, thus the search for novel
markers is of paramount importance. Since inflammation is associated with cancer progression and angiogenesis,
we investigated expression of cytokines like IL-6 and other mediators that play a key role in the innate immune
system, in particular toll like receptor 4 (TLR4), in the microenvironment of lesions from different stages of colon
disease progression, from ulcerative colitis to adenoma and adenocarcinoma to find useful markers.
Methods: The presence of inflammatory cells and expression of key cytokines involved in the inflammation
process were quantified by immunohistochemistry in specific tissue compartments (epithelial, stromal, endothelial)
by immunohistochemistry. A murine azoxymethane/dextran sulfate model in which Tir8, a negative regulator of
the inflammatory response, was ablated was used to confirm the clinical observations. 116 Archival tissue samples
from patients with different stages of colorectal disease: 13 cases of ulcerative colitis (UC), 34 tubular or tubulo-
villous adenomas (AD), and 53 infiltrating adenocarcinomas. 16 specimens of healthy mucosa surgically removed
with the cancerous tissue were used as a control.
Results: The differences between healthy tissues and the diverse lesions was characterized by a marked
inflammatory-angiogenic reaction, with significantly (P < 0.05) higher numbers of CD68, CD15, and CD31
expressing cells in all diseased tissues that correlated with increasing grade of malignancy. We noted down-
regulation of a potential modulator molecule, Hepatocyte Growth Factor, in all diseased tissues (P < 0.05). TLR-4
and IL6 expression in the tumor microenvironment were associated with adenocarcinoma in human samples and
in the murine model. We found that adenocarcinoma patients (pT1-4) with higher TLR-4 expression in stromal
compartment had a significantly increased risk in disease progression. In those patients with a diagnosis of pT3
(33 cases) colon cancer, those with very high levels of TLR-4 in the tumor stroma relapsed significantly earlier than
those with lower expression levels.
Conclusions: These data suggest that high TLR-4 expression in the tumor microenvironment represents a possible
marker of disease progression in colon cancer.
Background
Colorectal carcinoma (CRC) is the fourth most frequent
cause for death from cancer worldwide. Disparate fac-
tors increase a person’sr i s ko fd e v e l o p i n gt h et u m o r ,
such as age, inflammatory bowel disease, personal and/
or family (such as hereditary nonpolyposis colorectal
cancer; HNPCC) history of colorectal tumors (adenoma
or adenocarcinoma), and environmental factors [1-3].
The molecular genetic alterations along the process
leading to colon cancer is one of the best characterized
of all the processes in cancer progression [4]. However,
much less is known concerning the role of the tumor
microenvironment of CRC [5]. The development of a
tumor alters the homeostasis of the surroundings tissues
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activation of inflammation and of innate and adaptive
arms of the immune response [6,7]. The observations
that many tumors contain numerous inflammatory leu-
kocytes, and that chronic inflammation predisposes to
certain cancers, particularly colorectal cancer, histori-
cally led to develop the concept of a functional link
between chronic inflammation and cancer [8].
Chronic inflammation could promote colon carcino-
genesis by inducing gene mutations, inhibiting apoptosis
or stimulating angiogenesis and cell proliferation [9], as
well as inducing epigenetic alterations associated with
cancer development. In spite of this extensive evidence
indicating a role for inflammation in both colon cancer
insurgence and progression, there is relatively little
i n f o r m a t i o no ni n f l a m m a t i o n - associated microenviron-
mental changes associated with hyperplasia/neoplasia
development and its evolution towards invasive colorec-
tal adenocarcinoma. Tumors produce molecules that
attract a constant influx of inflammatory cells. Recent
studies have shown that immune cell infiltration of dys-
plastic lesions, based on pan-leukocyte CD45 staining,
increases with increasing malignancy of the lesions,
including breast, prostate and skin cancer development
[10-12]. Once within the tumor microenvironment,
these cells are polarized toward an alternative activation
[8] where they can stimulate initiated cell proliferation,
stromal disruption, and tumor growth [13,14]. Currently,
there is increasing evidence that the innate immune sys-
tem plays a key role in orchestrating angiogenesis in
cancer, producing angiogenic factors that enhance
endothelial cell recruitment, proliferation and new vessel
formation [15-18], contributing to tumor promotion and
other pathological conditions [12,13,15-17,19]. Although
chronic inflammatory conditions clearly predispose to
CRC, and use of anti-inflammatory agents can prevent
adenomas [20,21] and CRC [22,23], the role of immune
cell infiltration into CRC is controversial, as some stu-
dies have suggested that increased immune cell infiltra-
tion is beneficial [24,25].
Several cytokines appear to correlate with CRC pro-
gression, key among these is IL-6, an inflammatory cyto-
kine secreted in response to damage. IL-6 levels are
increased in most epithelial tumors [26], and high
serum IL-6 levels have been found to correlate with a
poor clinical prognosis in patients with diverse carcino-
mas (renal, ovarian and colorectal) [27-30]. Given the
observed involvement of IL-6 and its downstream tar-
gets in the regulation of cell proliferation, survival, and
metabolism, it is not surprising that IL-6 signaling has
also been implicated in tumorigenesis [31], and it has
been suggested that it has a possible oncogenic role,
driving expression of central hubs in cancer such as
STAT3 [32]. IL-6 is a downstream product of activation
of NF-B, a fundamental molecular hub linking inflam-
mation and cancer [33]. IL-6 is a key mediator in a
mouse model of microbially induced CRC [34]. NF-B
and IL-6 expression is induced by activation of specific
pattern recognition receptors, such as Toll-Like Recep-
tor 4 (TLR-4) [35]. TLR-4 is a transmembrane pattern
recognition receptor that provides a critical link between
immune stimulants produced by microorganisms, in
particular lipopolysaccharide, and the initiation of the
innate immune reaction to foreign agents, but also to
tumor cells [36]. TLR-4 has been found to be expressed
by leukocytes [37], endothelial cells [38], and epithelial
cells [39]. In the gut, activation of TLR-4 in enterocytes
leads to an inhibition of enterocyte migration and prolif-
eration as well as to the induction of enterocyte apopto-
sis-factors that would be expected to promote intestinal
injury while inhibiting intestinal repair. Moreover,
epithelial TLR signaling, acting in concert with TLR sig-
naling by leukocytes, participates in the development of
intestinal inflammation [40]. Activation of TLR-4 leads
to induction of an inflammatory response mediated by
multiple pathways and stimulates the production of
numerous cytokines, in particular IL-6 [35]. It has been
also demonstrated that TLR-4 signaling is crucial for
colon carcinogenesis in chronic colitis, being responsible
for induction of COX-2, increased prostaglandin E2 pro-
duction, and activation of EGFR phosphorylation in
chronic colitis [21,41-43]. Since in previous studies we
reported that TLR-4 levels were up-regulated in the thy-
m u so fm y a s t h e n i ag r a v i sp a t i e n t s[ 4 4 ] ,s u g g e s t i n ga n
innate-immune mediated priming for subsequent auto-
sensitization to the acetylcholine receptor, we inves-
tigated the expression of IL-6 and TLR-4 across a
spectrum of tissues recapitulating diverse steps along
the evolution towards colon cancer. The investigated tis-
sues included resection margins from radical surgery
(R0, presumed to be healthy, although field effects can-
n o tb er u l e do u t ) ,i n f l a m e dm u c o s af r o mp a t i e n t sw i t h
ulcerative colitis, adenomas and adenocarcinomas. We
examined 3 specific compartments in each tissue, the
epithelial compartment, the stroma and endothelial
compartment. Additionally, we studied tumor tissues
derived from animals lacking Tir8, an interleukin-1/
Toll-like receptor family member highly expressed in
the intestinal mucosa [45] in the azoxymethane and
dextran sulfate sodium salt (DSS) model of CRC. In this
mouse model of colonic carcinigenesis, the lack of con-
straints to NF-B driven inflammation, mediated via
interleukin-1 inhibition, allows investigation of the
effects of enhanced inflammation.
We observed a strong correlation between the
increased expression of IL-6 and TLR-4 with increasing
tissue dysplasia up to malignancy, higher TLR-4 and
IL-6 was also found in tumor tissues derived from
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Hepatocyte Growth Factor (HGF) was markedly down-
regulated in all the diseased tissues (ulcerative colitis,
adenoma or adenocarcinoma) studied.
As these data suggested involvement of innate
immune mediated mechanisms, we also examined mar-
kers representative of the innate immune network
involved in tumor reactive inflammation and inflamma-
tion-driven angiogenesis, including: CD31, expressed on
continuous endothelia and is a surface receptor for acti-
vated leukocytes that favors leukocyte diapedesis [46];
CD68, highly expressed in monocytes and tissue macro-
phages and involved in endocytosis and lysosomal traf-
ficking [47]; and CD15, also known as Lewis X, a
marker for mature granulocytes suggested to increase
the growth of tumor cells [48]. We observed a strong
correlation between the increased expression of these
inflammation markers and increasing tissue dysplasia up
to malignancy.
Materials And Methods
Patient samples
This study was conducted on 116 formalin fixed and
paraffin embedded tissue blocks corresponding to sam-
ples from four different steps of disease progression: 13
cases of ulcerative colitis (UC), 34 tubular or tubulo-
villous adenomas with low (29 cases) to high (5 cases)
grade dysplasia (AD), and 53 infiltrating adenocarcino-
mas classified using TNM (ajcc, american joint commit-
tee on cancer, VI edition) with T1 (7 cases,), T2 (10
cases), T3 (33 cases), and T4 (3 cases) (AC) (complete
patient characteristics are in Additional file 1, Supple-
mental Table S1). Sixteen specimens of healthy mucosa
(R0, radical resection margins) surgically removed with
the cancerous tissue were used as a control. For the ade-
nocarcinoma patients, follow-up of up to 9 years was
available.
Animal model of colitis-associated cancer in Tir8-/- mice
Tir8-deficient (Tir8-/-) mice were generated as pre-
viously described [49]. We used 8-12 week old mice on
a C57Bl/6 (H2
b) genetic background. C57Bl/6 (Tir8+/+)
were used as wild-type (WT) controls. To induce colon
tumors, mice were treated with azoxymethane followed
by three cycles of 1.5% DSS as previously described [24].
Briefly, a single dose (10 mg/kg) of the mutagenic
agent azoxymethane (Sigma) was injected in Tir8-/- and
wild type (WT) control mice, followed by 3 cycles of
3%, 2%, or 1.5% DSS (molecular mass, 40 kDa; ICN) dis-
solved in sterile, distilled drinking water. At the end of
the treatment, after 60 days, mice were euthanized, the
large intestine was removed, open longitudinally, rinsed
and “rolled” and processed for histological and immuno-
histochemistry analysis, providing a complete spectrum
of the length of the large intestine in each section.
Research projects involving animals were first approved
by Italian National Institute of Health (ISS), then experi-
ments were performed following protocol registered
with number 18/17/2004, approved by Istituto Clinico
Humanitas (ICH) ethical committee. The care and use
of the animals were in compliance with laws of the Ita-
lian Ministry of Health (D.L. N. 116/1992) and the
guidelines of the European Community.
Histological analysis and immunohistochemistry
Three micrometer tissues of the paraffin-embedded sec-
tions of human specimens were mounted on slides
coated with silane (Dako, Milan, Italy) and stained with
hematoxylin for histological analysis. For analysis of
murine tissues, after sacrificet h el a r g ei n t e s t i n e so ft h e
treated mice were removed, fixed in 10% neutral buf-
fered formalin, and embedded in paraffin. Three-micro-
meter-thick consecutive sections that covered the entire
length of the “rolled” colon were cut and mounted on
silanized slides.
Hematoxylin-Eosin staining (H&E) was performed
according to standard protocols. For immunohistochem-
istry, slides were deparaffinized in xylene and rehydrated
in a series of graded alcohols, and the antigen was
retrieved in 0.01 mol/L sodium citrate buffer or EDTA
ph 8 0.5M. Sections were then treated with 3% of
hydrogen peroxide to inhibit endogenous peroxidase.
The sections were stained with primary antibodies, listed
in Table 1, followed by appropriate secondary antibody,
then the Dako REAL EnVision system, Peroxidase/DAB
+, Rabbit/Mouse was used as revelation system accord-
ing to the manufacturer’s recommendations. The reac-
tion was visualized by use of the appropriate substrate/
chromogen (Diaminobenzidine, DAB) reagent. Counter-
staining was performed using Mayer’s hematoxylin
(Sigma, Taufkirchen, Germany).
Image acquisition and rendering
Bright field images of H&E and antibody-stained
sections were visualized with a Nikon E800light micro-
scope, and photomicrographs taken at a 400× magnifica-
tion using a digital image acquisition system.
Quantification of staining and statistical analysis
Positive staining was identified when the epithelial,
endothelial cells or stroma showed clear brown staining
and quantified by counting the positive cells in 3 repre-
sentative areas for each section, and expressing this as a
percentage of average number of positive cells/section.
Stroma was defined as the connective tissue areas
around the tumor cells along with any immune infiltrate
in these areas that were clearly not epithelial or tumor
cells, or vessels. Statistical differences between individual
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t-test (Mann-Whitney) where P values < 0.05 were con-
sidered statistically significant. Regression analysis was
also performed to test statistical significance of correla-
tion between the expression of selected markers.
P values < 0.05 were considered statistically significant.
All data were analyzed using the Prism (Graph Pad) sta-
tistics and graphing program.
Disease free survival (time from diagnosis to relapse,
progression or death of disease) were estimated for each
marker by means of Kaplan Meier method for patients
with CRC using the Survival Analysis System Excel
addin by SG Shering, Univ College of Dublin. The med-
ian value of the percentage of expression for each mar-
ker in any tumor compartment was used as cut-off.
Statistical differences between groups were evaluated by
the Log-rank test.
Results
Expression of cytokines and TLR-4 in specific tissue
compartments
The histological features of different types of disease
analyzed in this study are shown in figure 1, where the
different degrees of malignancy are apparent. We could
readily discern 3 specific compartments within each tis-
sue, an epithelial compartment, an endothelial compart-
ment (confirmed by CD31 staining, see below) and a
stromal compartment, and immuno-reactivity was
examined within each compartment (Table 2).
The immuno-reactivity for IL-6 was mostly observed
in the epithelial and stromal compartments (Figure 2,
Table 2). The frequency of IL-6-producing cells within
the epithelial and stromal compartments of healthy
colon tissues were 4.9% and 7.1%, respectively. The
initiation of the neoplastic process corresponded to an
expansion of IL-6+ cells in these tissue compartments,
rising to 11.2% and 17.3% in UC specimens, to 21.5%
and 27.9% in AD, and, finally, to 32% and 34.6% in AC.
The observed values in the diseased tissues were
statistically different when compared with the values of
healthy specimens (p < 0.05) (Figure 2, Table 2). This
trend was also confirmed in the endothelial compart-
ment of healthy and tumor tissues, with the comparison
between IL-6+ cells in AC (6.8%) and healthy tissue
(2.9%) being significant (p < 0.05) (Figure 2, Table 2).
TLR-4+ cells were preferentially distributed within
the epithelial and stromal compartments of all the spe-
cimens, although in different percentages (Figure 3,
Table 2). The increased presence of TLR-4-expressing
cells corresponded to an increasing grade of dysplasia
(Figure 3). In particular, the averaged percentage of
TLR-4+ cells in the epithelial and stromal compart-
ments of healthy tissues were 3.6% and 5.8%, respec-
tively. These values increased to 8.2% and 16.1% within
the epithelial and stromal areas of UC specimens (p <
0.05). In AD tissues the TLR-4+ cells rose to 16.8%
and 25.4%, respectively (p < 0.05 when compared with
percentage of TLR-4+ cells in healthy tissues and UC),
while in AC their levels additionally increased up to
five times (19.6% and 28.2%, in the epithelial and stro-
mal compartments, respectively; p < 0.05). In the
stroma, TLR-4 expression was largely due to immune
cells showing a morphology typical of macrophages
[50,51].
When we examined the endothelial compartment, we
also found a trend towards an increase in TLR-4-expressing
cells paralleling tumor progression. In particular, the per-
centage of positive cells in AD and AC (6.6% and 8.0%,
respectively) significantly differed from the values observed
in the endothelium of healthy tissues (2.44%) (p < 0.05 for
all comparisons) (Figure 3, Table 2).
In pT3 AC (33 cases), a positive correlation was
observed between the expression of IL-6 and the pre-
sence of TLR-4+ cells in the stromal and epithelial com-
partment (R
2 = 0.16, p < 0.05, and R
2 = 0.33, p < 0.05,
respectively), and between the expression of IL-6
and the presence of CD15+ cells in the stromal com-
partment (R
2 = 0.23, p < 0.05).
Table 1 Primary antibodies used for immunohistochemical detection
Primary antibody Species raised in Species directed to Supplier (clone and/or #) Dilution
CD68 Mouse Human DAKO (PG-M1, #M0876) 1: 100
CD15 Mouse Human DAKO (C3D-1, #M0733) 1: 20
CD31 Mouse Human DAKO (JC70A, #M0823) 1: 20
TLR-4 Rabbit Human SANTA CRUZ BIOTECHNOLOGY (M-300, #sc-30002) (Santa Cruz,
California, USA)
1: 100
Mouse NOVUS BIOLOGICALS (NB100-56581) (Littleton, CO, USA) 1:600
HGF Goat Human SIGMA (H7157) 1: 400
IL-6 Rabbit Human NOVUS BIOLOGICALS
(NB600-1131)
1: 400
Mouse ABCAM (ab6672) (Cambridge, UK) 1:400
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ing the frequency of HGF-secreting cells in healthy
and pathological specimens. We observed the highest
number of HGF+ cells in healthy tissues (35.1%), the
incidence of HGF+ cells decreased sharply in speci-
mens of UC (15.5%, p < 0.05), AD (19.4%, p < 0.05),
and AC (17.3%, p < 0.05) (Figure 4, Table 2). Notably,
in tumor sections, the HGF positive cells were limited
to the epithelial compartment, suggesting that HGF in
the colon is a marker of an intact normal epithelium,
and is down-regulated during the inflammatory
response.
Expression of IL-6 and TLR-4 in a murine CRC model
We compared our findings on IL-6 and TLR-4 in
human tissues with inflammation-tracking in a mouse
model of experimentally-induced colitis-associated can-
cer in Tir8 deficient mice. After treatment with the
azoxymethane and DSS carcinogenic regimen, all mice
developed tumors, regardless of genetic background.
However, a higher numbers of lesions developed in the
Tir8 -/- mice, and these lesions were higher grade ade-
nomas as compared to those that developed in the WT
mice, consistent with previous reports [45]. Immuno-
histochemical analyses of the colons from WT and
Tir8 -/- mice indicated higher staining for TLR-4 and
IL-6 in the neoplastic tissues of specimens from Tir8-
deficient mice as compared with neoplastic tissues
from WT animals (Figure 5a). Moreover, in KO mice,
the values of TLR-4 in the stromal compartment
(again associated with cells of macrophage morphol-
ogy) of the adenocarcinomas were elevated and statisti-
cally different form the values of adenoma specimens
(p < 0.05) (Figure 5b).
Similar results were observed when we compared the
values of the adenomas of both WT and KO mice with
the adenocarcinomas that developed only in KO mice
(data not shown).
Relationship between TLR-4 and disease-free survival
time
Given the consistent relationship between expression
and progression of IL-6 and TLR-4 in human samples
and murine models, we evaluated the disease free sur-
vival time of patients affected by CRC as a function of
marker expression in each tissue compartment. Statis-
tically significant results were obtained for TLR-4
expression in the tumor stroma compartment. In parti-
cular, we observed that CRC patients (adenocarcino-
mas, pT1-4) with a percentage of TLR-4+ cells in the
tumor stromal compartment lower than the median
value (20% of the cells positive) relapsed with a greater
time interval and several showed survival of over 100
months, while those patients with a percentage of
TLR-4+ cells in the stromal compartment higher than
the median value relapsed earlier and fewer showed
long term survival (RR 2.36; log rank chi-square 4.25,
p < 0.05) (Figure 6a).
Figure 1 Hematoxylin and Eosin staining. Examples of hematoxylin and eosin (H&E) staining of healthy tissues (A), ulcerative colitis (B),
adenomas (C) and adenocarcinomas (D) (magnification ×100).
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Condition Healthy % (+ SEM) Ulcerative colitis (UC) % (+ SEM) Adenoma (AD) % (+ SEM) Adenocarcinoma (AC) % (+ SEM)
Compartment Endothelium Epithelium Stromal Endothelium Epithelium Stromal Endothelium Epithelium Stromal Endothelium Epithelium Stromal
Marker
CD31 6.7 (± 0.5) n.d. n.d. 10.5(± 0.5) n.d. n.d. 11.2(± 0.9) n.d. n.d. 14.6(± 1) n.d. n.d.
HGF n.d. 35.1(± 2.1) n.d. n.d. 15.5(± 1.3) n.d. n.d. 19.3(± 1.5) n.d. n.d. 17.3(± 1.5) n.d.
CD68 n.d. n.d. 8.7(± 1.0) n.d. n.d. 18(± 0.8) n.d. n.d. 23(± 2.3) n.d. n.d. 26.6 (± 1.8)
CD15 1.4(± 0.3) 1 (± 0.4) 2.5(± 0.6) 2.6(± 0.2) 4.7(± 0.7) 7.0(± 1.3) 3.3(± 0.4) 11.6(± 2.4) 16.(± 1.9) 3.6(± 0.6) 13.4(± 1.0) 22.8(± 2.5)
TLR-4 2.4(± 0.3) 3.6(± 0.9) 5.8(± 1.5) 4.0(± 0.4) 8.2(± 1.6) 16.1(± 1.5) 6.6(± 0.5) 16.8(± 2.5) 25.4(± 2.8) 8.0(± 0.8) 19.6(± 3.3) 28.2(± 2.7)
IL-6 2.9(± 0.2) 4.9(± 0.5) 7.06(± 0.2) 4.1 (± 0.3) 11.2(± 1.2) 17.2(± 1.4) 6(± 0.4) 21.5(± 2.0) 27.9(± 3.2) 6.8(± 0.8) 32.0(± 3.0) 34.6(± 2.7)
Shown are the averaged percentages of cells (± Standard Error of the Mean-SEM) positive for staining within each tissue compartment. UC = ulcerative colitis; AD = adenomas; AC = adenocarcinomas; n.d. = not
detected.
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6We then examined the largest group, adenocarcinoma
pT3 patients (33 cases), using as cut off a high percen-
tage of expression (≥50% of the cells positive) we discri-
minated two different trends. Again, those patients with
the highest TLR-4 expression relapsed early (within 14
months), while those with lower expression relapsed
much later (within 40 months, RR 3.15; log rank chi-
square 4.03, p < 0.05) (figure 6b).
Given the relationship between TLR-4 expression and
survival in adenocarcinomas, and the general tendency
towards increased inflammatory markers as a function
increasing tissue dysplasia up to malignancy, we then
investigated several markers of inflammatory cells and
angiogenesis.
Expression of inflammation markers with increasing
tissue dysplasia
Immunohistochemical analysis showed that CD68+ cells
progressively colonized the tumor stroma, being
almost absent in the healthy tissue, clearly present in
pre-cancerous conditions, and peaking in samples from
patients with adenocarcinomas (Figure 7, Table 2). In
particular, positive staining for CD68 was 8.7% in
healthy tissue, 17.9% in samples from patients with UC,
23.0% in AD, and 26.6% in AC (all p < 0.05, as com-
pared to healthy tissue). A statistically significant differ-
ence was also observed comparing the percentage of
CD68+ cells between specimens of UC and AC (p <
0.05). The staining pattern was consistent with localiza-
tion to macrophages within the stroma.
This trend was even more evident when analyzing
the distribution of CD15+ (Figure 8, Table 2). In this
case clear compartment-specific differences were
observed; the percentage of CD15+ cells present in the
stromal and epithelial compartments of UC were sig-
nificantly less than the number of CD15+ cells
observed in the same compartments of AD, and AC
tissues, respectively (p < 0.05 in all comparisons)
(Figure 8, Table 2). In the healthy, UC and AD tissues,
the staining pattern was largely associated with
neutrophils, while CD15 expression was more widely
distributed in the AC tissues.
Figure 2 IL-6 expression in human colon tissues. 2a Expression of IL-6 in normal healthy tissues (A), ulcerative colitis (B), adenomas (C) and
adenocarcinomas (D); some scattered epithelial and stromal cells are stained with weak intensity. In the dysplastic conditions there is an
increased staining (magnification ×400). 2b Different expression of IL-6 in endothelial, epithelial and stromal compartments show that in all
groups this marker is significantly increased respect to healthy tissues (mean ± SEM; **P < 0.01, *** P < 0.001). HT = healthy tissues (N = 16); UC
= ulcerative colitis (N = 13), AD = adenomas (N = 34; 29 low and 5 high grade), AC = adenocarcinomas (N = 53; 7 T1, 10 T2, 33 T3, 3 T4).
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Immunostaining with anti-CD31 antibody showed an
increased density of vessels, identified by the presence
of a lumen, in pathological specimens compared with
healthy tissues (Table 2). In particular, the percentage
of CD31+ cells in healthy tissues was 6.67%, and it rose
to 10.55% in UC (p < 0.05), 11.21% in AD (p < 0.05),
and 14.59% in AC (Figure 9, Table 2). The observed
percentage of CD31+ cells in adenocarcinoma speci-
mens was twice that of controls (14.59%, P < 0.05), and
it was significantly increased in comparison with the
percentage of CD31+ cells observed in UC tissues (Fig-
ure 9, Table 2).
Discussion
The tumor microenvironment is a complex network of
different cell types and numerous intracellular media-
tors, including inflammatory and other immune cells,
stromal, endothelial, and epithelial cells. These elements
appear to actively participate in tumor progression and
dissemination, where the tumor microenvironment not
only responds to and supports carcinogenesis, but also
contributes to tumor initiation, progression, and metas-
tasis. The mutual interaction between transformed cells
and the microenvironment modifies tumor fate.
Although neoplastic transformation in inflammatory
bowel disease (IBD) is thought to be similar to the ade-
noma-carcinoma sequence in sporadic CRC, several dif-
ferences exist. While in colitic mucosa the dysplasia is
usually multifocal, suggesting a “field effect”, in sporadic
CRC the preneoplastic lesions are usually focal and
mass forming. There are also several differences in the
sequences of molecular events leading from dysplasia to
invasion in adenocarcinoma arising in IBD as compared
with sporadic CRC. For example, loss of APC function
is a common and early event in sporadic CRC, while it
is a much less frequent, and usually late, event in the
colitis-associated dysplasia-carcinoma sequence. Further,
in patients with colitis-associated cancer, p53 mutation
is an early event that may also be detected in the non
dysplastic mucosa, while it is late in sporadic CRC [52].
There is a clear relationship between chronic inflam-
mation and colon cancer, however, the exact mediators
by which chronic inflammation promotes colorectal
Figure 3 Expression of TLR-4 in human colon tissues. 3a TLR-4 immunohistochemistry analysis. Different expression of TLR-4 in healthy
tissues (A), ulcerative colitis (B), adenomas (C) and adenocarcinomas (D) show that increasing grade of dysplasia directly correlates with higher
expression of this marker (magnification ×400). 3b Different expression of TLR-4 in endothelial, epithelial area and stromal department shows
that in all groups TLR-4 is significantly increased respect to healthy tissues (mean ± SEM; **P < 0.01, *** P < 0.001). HT = healthy tissues (N = 16);
UC = ulcerative colitis (N = 13), AD = adenomas (N = 34; 29 low and 5 high grade), AC = adenocarcinomas (N = 53; 7 T1, 10 T2, 33 T3, 3 T4).
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Page 8 of 16carcinogenesis are still unclear. Persistent inflammation
is believed to result in increased cell proliferation as
well oxidative stress that leads to the development of
dysplasia [9]. Oxidative stress is particularly intense in
inflammatory conditions, largely due to extensive neu-
trophil and macrophage recruitment. These cells
become activated in the inflamed tissue and produce
substantial quantities of reactive oxygen species (ROS)
and reactive nitrogen (RON), leading to DNA damage,
including gene mutations, genetic instability and aber-
rant methylation. RONs may interact with genes
involved in colorectal carcinogenetic pathways such as
p53, DNA mismatch repair genes and other factors such
as NF-B and COX-2 [21,53-55].
Here we studied the expression patterns of selected
inflammatory and angiogenesis markers in tissue speci-
mens with increasing tissue dysplasia into colorectal
tumor progression. Analyzing samples from predispos-
ing conditions (such as ulcerative colitis) to neoplastic
pre-cancerous lesions to invasive cancer, we detected a
significant increase in angiogenesis using CD31 staining,
inflammatory cells expressing CD68 or CD15, cytokines
like IL-6 and other mediators that play a key role in the
innate immune system, in particular TLR4. Further, a
distinctive pattern of cells and cytokines within the tis-
sue compartments, tumor and microenvironment, could
be identified. Specifically, we found a more intense
staining for all the inflammatory markers in the stromal
compartment of AC samples, indicating that these
major players of inflammation infiltrate tumor tissues.
High levels of tumor infiltration by T cells (using CD3)
or memory T cells (CD45RO) in both the invasive mar-
gin and tumor center has been associated with better
clinical outcome [25], suggesting that these could be
useful markers of prognosis. However, additional studies
examining the postsurgical development of metachro-
nous metastases indicated that levels of CD3+ cells infil-
trating into the invasive margin was not an independent
Figure 4 Expression of HGF in human colon tissues. 4a Different expression of HGF (present only in epithelial compartment) in healthy
tissues (A), ulcerative colitis (B), adenomas (C) and adenocarcinomas (D). The peak of immunoreactivity is in the healthy tissue. In contrast, in the
dysplastic lesions, there is a drop in expression as the grade of dysplasia increases. The lowest expression is in UC cases (magnification ×400). 4b
Expression of HGF in healthy tissues (HT), UC, AD and AC. In all groups HGF is significantly reduced respect to healthy tissues (mean ± SEM; **P
< 0.01, *** P < 0.001). HT = healthy tissues; UC = ulcerative colitis, AD = adenomas, AC = adenocarcinomas.
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Page 9 of 16predictor of clinical outcome in patients with stage III
colorectal cancer [56]. IL-6 activates a feed-forward loop
leading to increased STAT3 activation in cancer and
inflammatory cells [32], where STAT3 promotes polari-
zation of innate immunity towards immuno-suppressive
alternate activation. Our results indicate the innate
response related to activation of the TLR4-IL6 axis
found here would be associated with repression of adap-
tive anti-tumor immune responses.
We hypothesize a scenario where the microenviron-
mental contribution to tumor progression also could be
segmented in a multistep process, the first step being
Figure 5 Staining in murine models of colorectal cancer. Comparison of H&E, TLR-4 and IL-6 immunostaining in mice wild type and knock-
out for Tir8. Tir8 -/- mice had a higher grade of dysplasia and an increased expression of TLR-4 and IL-6 than wt mice (magnification ×400).
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Page 10 of 16Figure 6 Disease Free Survival (DFS) curves of adenocarcinoma patients associated with TLR-4 expression in the tumor stroma. Disease
free survival (time from diagnosis to relapse, progression or death of disease) were estimated for each marker by means of Kaplan Meier method
for patients with CRC using the Survival Analysis System Excel addin by SG Shering, Univ College of Dublin. 6a DFS curve of all adenocarcinoma
patients (pT1-4) (53 cases). CRC patients with a low percentage of TLR-4+ cells in the tumor stromal compartment (less than the median value
corresponding to 20% of the cells positive) relapsed with a greater time interval and several showed survival of over 100 months, while those
patients with a percentage of TLR-4+ cells in the stromal compartment higher than the median value relapsed earlier and fewer showed long
term survival (RR 2.36; log rank chi-square 4.25, p < 0.05). 6b DFS curve of patients with adenocarcinoma at the pT3 (33 cases) stage. Patients
with a percentage of TLR-4+ cells in the tumor stromal compartment more than 50% relapsed early (within 14 months), while those with a
percentage of TLR-4+ cells expression less than 50% relapsed much later (within 40 months, RR 3.15; log rank chi-square 4.03, p < 0.05).
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Page 11 of 16the transition from healthy mucosa to ulcerative colitis,
and corresponding to a massive inflammatory-angio-
genic reaction. In ulcerative colitis, inflammation
and angiogenic markers showed significantly higher
expression than in healthyt i s s u e s .H G F ,am e d i a t o r
with significant anti-inflammatory activity [57], particu-
larly in the gastrointestinal tract [58] where it appears to
suppress inflammation by acting on NFB pathway and
affecting downstream factors such as TLR4-IL6 [57],
was expressed at high levels only in the controls. In con-
trast, pro-inflammatory markers (IL6, CD68, CD15,
TLR4) expression is higher in adenocarcinoma tissues
respect to the adenoma, the ulcerative colitis and the
healthy tissues.
Lack of control of the host reaction to tumor growth
is essential for tumor progression. In addition to
repressed HGF, we validated the enhancement of TLR-
4-bearing and IL-6-secreting cells in adenocarcinoma
specimens of colitis-associated cancer developed in mice
lacking the expression of Tir8, an inhibitory member of
the interleukin-1 receptor family that acts as a negative
regulator of NF-B activation in response to TLRs and
interleukin 1 receptor agonists [59]. This correlates with
the protection from AOM induced colorectal cancer in
TLR4-/-mice [41], suggesting that TLR4 signaling plays
a role in CRC progression.
Chronic inflammation and related abnormalities in the
gut flora as observed in IBD, are associated with a
higher incidence of colon cancer. TLR-4 is a key pattern
recognition receptor that mediates innate immune
responses to pathogen-associated molecules, most nota-
bly the lipopolysaccharides (LPS) of Gram-negative bac-
teria, triggering phagocyte activation and shaping
adaptive immune responses [60]. TLR-4 also recognizes
endogenous ligands produced by tissue damage, includ-
ing fragments of extracellular matrix molecules such as
hyaluronic acid, heparan sulfate, and proteoglycans, as
well as intracellular proteins, in particular the proinflam-
matory high-mobility group box 1 (HMGB1) protein
[60]. These ligands trigger inflammation and tissue
Figure 7 CD68 immunostaining in human colon tissues. 7a CD68 immunostaining in healthy tissues (A), ulcerative colitis (B), adenomas (C)
and adenocarcinomas (D) shows a growing expression of intensity, percentage of positive cells and density in stromal compartment
(magnification ×400). 7b Expression of CD68 in the stromal compartment of the different groups. In all groups CD68 is significantly increased
respect to healthy tissues (mean ± SEM; **P < 0.01, *** P < 0.001). HT = healthy tissues (N = 16); UC = ulcerative colitis (N = 13), AD =
adenomas (N = 34; 29 low and 5 high grade), AC = adenocarcinomas (N = 53; 7 T1, 10 T2, 33 T3, 3 T4).
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Page 12 of 16repair responses [60], Akt activation [50] that is often
associated with tumors and tumor progression [8,17,19].
Changes induced by unbalanced inflammation and bac-
teria could contribute to colon cancer development
through release of LPS that binds TLR-4 present on the
surface of inflammatory cells, and induce an inflamma-
tory reaction. Consistent with an increased expression
with advancing disease, TLR-4 expression was associated
with different survival of patients with invasive colon
AC. We observed that AC patients who had a percen-
tage of TLR-4+ cells in the tumor stromal compartment,
(mostly immune cells), lower than the median value had
fewer relapses, and the relapses that occurred did so
after a longer lag time that those AC patients with
higher TLR-4 expression. Recent independent studies
also found a correlation between TLR4 expression and
patient survival in adenocarcinomas [61], although the
study was limited to tumor cell expression and the role
for these markers in less malignant conditions or other
markers of inflammation were not investigated.
Conclusion
Here we show enhanced expression of TLR-4 on cells of
the epithelial and stromal tissue compartment as well as
players in the inflammatory and angiogenic pathways
are strongly increased during colorectal cancer progres-
sion. Our data corroborate the concept that inflamma-
tion correlates with the degree of malignancy in colon
Figure 8 CD15 expression in human colon tissues. 8a CD15 immunostaining in healthy tissues (A), ulcerative colitis (B), adenomas (C) and
adenocarcinomas (D). The figure shows an increasing expression in all the compartments: endothelial, epithelial and stromal. In the AC tissues
there is a wide distribution and a strong intensity of the marker (magnification ×400). 8b Expression of CD15 in three different compartment
shows that in all groups CD15 is significantly increased respect to healthy tissues (mean ± SEM; **P < 0.01, *** P < 0.001). HT = healthy tissues
(N = 16); UC = ulcerative colitis (N = 13), AD = adenomas (N = 34; 29 low and 5 high grade), AC = adenocarcinomas (N = 53; 7 T1, 10 T2, 33
T3, 3 T4).
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Page 13 of 16cancer and provides innovative data on the role of sig-
naling by TLR-4 both in the tumor and the microenvir-
onment. Accordingly, TLR-4 appears to have the
potential to become a marker of disease progression in
patients with colon malignancies or pre-malignant
lesions.
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